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A decrease in the level of the ROC1 protein, which is involved in cyclin D1 degradation, might explain an
increase in cyclin D1 protein in the absence of gene overexpression. This study aimed to investigate the
relationship between ROC1 and cyclin D1 expression in skin melanomas. A total of 62 cases of primary
skin melanomas and 58 cases of compound melanocytic nevi were assessed. Immunohistochemistry was
performed using cyclin D1 and ROC1 antibodies, and ﬂuorescent in situ hybridization was used to assesselanoma
yclin D1
OC1 protein
CND1 gene
biquitination
the ampliﬁcation of the CCND1 gene. ROC1 was expressed in >50% of cells in 87.9% of the melanocytic
nevus cases and in 45.2% of the melanoma cases (p=0.0014). There was a signiﬁcant negative correlation
between ROC1 and cyclin D1 expression in all cases (p=0.0008985). In comparison with cyclin D1, ROC1
expression was increased in 86.2% of the melanocytic nevi and in 45.2% of the melanomas (p<0.001).
Among thenon-ampliﬁedmelanomas, 50% expressed cyclinD1 in >50%of the cells and expressedROC1 in
nega
lin D1<25%. ROC1 expression is
in the degradation of cyc
ntroduction
The transformation ofmelanocytes tomelanoma cells is charac-
erized by an abnormal proliferation that results fromalterations in
he two major cell cycle regulatory pathways: the retinoblastoma
rotein (pRb) and p53 tumor suppression pathways [18]. Nearly all
elanoma cell lines tested to date have shown pRb pathway alter-
tions due to p16 or pRb deﬁciency, cdk4 mutation, or cyclin D1
verexpression [18,29].
In all types of melanoma, the most frequently ampliﬁed region
s chromosome 11q13 [2,3], which harbors the cyclin D1 gene.
lthough cyclin D1 is a well-known growth promoter, it may also
unctionas a survival factor for tumor cells [27,31]. CyclinD1ampli-
cation or overexpression is a crucial event that leads tomelanoma
rogression [10] and is associated with high proliferation rates in
hese tumors [17,29]. Failure to downregulate cyclin D1 overex-
ression in melanocytic cells probably promotes cell proliferation
nd prevents differentiation [29].CyclinD1 is anuclearproteinencodedby theCCND1gene,which
s located at chromosome 11q13. CCND1 ampliﬁcation has been
etected in over 44% of acral lentiginous melanomas, but much
ess frequently in other melanoma subtypes [27,31].
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Open access under the Elsevier OA license.tively correlated with cyclin D1 expression, demonstrating its importance
in melanomas.
© 2011 Elsevier Gm bH.    
All melanoma cases with an increased number of CCND1 copies
overexpress cyclin D1. However, about 25% of melanomas that
overexpress cyclin D1 have been found to have a normal number
of CCND1 copies, suggesting that cyclin D1 levels are modulated by
multiple mechanisms [4,18,27]. It is possible that cyclin D1 over-
expression is induced by a defect in its degradation that increases
its stability. Cyclin degradation is normally regulated by ubiquitin-
dependent proteolysis [19,24].
Different ubiquitin-dependent proteolytic pathways use
enzymes conjugated to different structurally similar ubiquitins.
These, in turn, are associated with recognition subunits of proteins
targeted by a particular degradation sign. The enzyme that, when
conjugated, addsubiquitin to a lysine residueof a target protein and
then, subsequently, adds a series of additional ubiquitins, forms a
polyubiquitin chain that is recognized by a speciﬁc receptor protein
in proteasomes [1,14]. Polyubiquitin chains are linked covalently to
the target protein through a cascade of three enzymes: ubiquitin-
activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and
ubiquitin-protein ligases (E3). In the last stage of this cascade, the
ubiquitin-protein ligase (E3) acts as a central component of the
ubiquitination pathway, catalyzing the ﬁnal transfer of ubiquitin
from E2 to the substrate [8,9,11,14,15]. The interaction of the E2
and E3 proteins is through protein fragments called RING ﬁnger
Open access under the Elsevier OA license.proteins. The SCF protein (SKP1-CUL1(CDC53)-F-box) and the
Anaphase Promoter Complex (APC) are the two major ubiquitin-
ligase complexes. They regulate ubiquitin-mediated proteolysis
during G1/S phase and anaphase, and they contain the small ROC1
and APC11 RING ﬁnger proteins, respectively [6,12,23].
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Several studies have demonstrated that the SCF-ROC1 pro-
ein is crucial for the ubiquitination of cyclin D1, D2, and D3 in
umans,playinga leading role in the regulationof cyclinproteolysis
19,24,32]. However, neither studies of the ROC1 immunohisto-
hemical expression pattern nor studies comparing ROC1 and
yclin D1 expression in melanomas or other tumors are available
n the literature.
The expression of d-cyclins correlates with melanoma malig-
ancy potential and prognosis. Thus, understanding the mech-
nism underlying d-cyclin overexpression can contribute to the
evelopment of therapeutic approaches for melanomas overex-
ressing these proteins. The purpose of this work was to assess
he relationship between ROC1 and cyclin D1 expression in skin
elanomas and melanocytic nevi.
aterial and methods
tudy groups
This cross-sectional, analytic study included 62 cases of primary
kin melanoma that were allocated into four groups, according
o melanoma thickness: Group 1: 15 cases of melanoma <1mm;
roup 2: 15 cases of 1.01–2mm melanoma; Group 3: 15 cases of
.01–4mmmelanoma; andGroup 4: 17 cases ofmelanoma >4mm.
total of 58 cases of compound melanocytic nevus were used as
ontrols (Group 5). The melanoma cases did not originate from
elanocytic nevi nor did they show histological regression. The
ample calculus was based on the prevalence of skin melanomas in
he general population.
mmunohistochemistry
Tissue sections 4m thick were cut, mounted on slides pre-
iously treated with poly-d-lysine, and immunostained according
o the ABC technique. Incubation with primary antibodies ROC1
clone RB-069-P, LABVISION, Westinghouse, USA; 1/800 dilution)
nd cyclin D1 (clone RBT14, BioSB, Santa Barbara, USA; 1/100 dilu-
ion)was carried out. The reactionwas developedwith DAB (Sigma
hemical Co., St. Louis, USA) for ﬁve minutes and counterstained
ithGiemsa [25]. Squamous epitheliumof tonsilwas used as a pos-
tive control for ROC1 immunolabeling, and normal breast tissue
as used as the control for cyclin D1.
A semiquantitative scoring system was used for the assessment
f immunohistochemical staining. Cell nuclei are either positive or
egative for ROC1 and cyclinD1. The percentage of tumor cellswith
ositive staining was determined and classiﬁed into four classes:
1) 0–25% of cells stained; (2) 26–50% of cells stained; (3) 51–75%
f cells stained; and (4) 76–100% of cells stained [27].
For comparative purposes, the following categories were used
o classify the relationship between ROC1 and cyclin D1 expres-
ion (ROC1/cyclin D1): (1) increased ROC1 in relation to cyclin
1 expression, or when the percentage of ROC1-positive cells was
igher than that of cyclin D1-positive cells; (2) proportional ROC1
nd cyclin D1 expression, or when the percentage of ROC1 pos-
tive cells was the same as that of cyclin D1-positive cells; and
3) increased cyclin D1 in relation to ROC1 expression, or when
he percentage of cyclin D1-positive cells was higher than that of
OC1-positive cells.
luorescent in situ hybridization (FISH)For FISH was used the Vysis® LSI® Cyclin D1 (11q13) Spectru-
Orange/CEP 11 SpectrumGreenTM Probe (Downers Groove, USA)
hat is a dual-color probe consisting of a red-labeled locus-speciﬁc
CCND1 gene) and a green-labeled speciﬁc chromosome 11 cen-
romeric region.and Practice 207 (2011) 174–181 175
A total of 60 nuclei from each sample were assessed using
FISHView/SPOTView (Applied Spectral Imaging, Israel) for the
quantiﬁcation of nuclear gene ampliﬁcation and analysis of differ-
ences in nuclear gene ampliﬁcation within the same tumor.
Gene ampliﬁcation was considered negative when the
CCND1/CEP11 ratio was <1.8; equivocal when the CCND1/CEP11
ratio was 1.8–2.2; and positive when the CCND1/CEP11 ratio was
>2.2 [27].
Statistical analysis
In order to detect differences in protein expression associated
with age, gender, lesion site, study group, melanoma type, and
Breslow thickness, the Chi-square test or the Fisher’s exact test
was used. A Spearman’s coefﬁcient was used to assess correlations
between expression levels. Signiﬁcance level was set at ˛=0.05 in
all tests.
Approval by the Research Ethics Committee
This study was approved by the Research Ethics Committee of
Botucatu Medical School – UNESP (OF. 79/2007-CEP).
Results
The patient median age was 60.5 years (23–89 years) in the
melanoma group and 30.5 years (4–71 years) in the melanocytic
nevus group.
The melanoma group was composed of superﬁcial, spreading
melanomas (SSM) (41.9%, n=26), followed by nodular melanomas
(20.9%, n=13), lentigo maligna melanoma (LMM) (19%, n=12),
acral lentiginous melanoma (16.6%, n=10), and one unclassiﬁed
melanoma.
ROC1 and cyclin D1 expression did not vary with age, gender, or
lesion site in either the melanoma or the melanocytic nevus group
(p>0.05).
The expression of ROC1 correlated with neoplasia type (benign
or malignant) (p=0.0014). Cyclin D1 protein expression also cor-
related with neoplasia type (p=0.000). In the melanocytic nevus
group, ROC1was expressed by >75%of the cells in 62.1% of the cases
(n=36), and by >50% of the cells in 87.9% (n=51) (p<0.05). Cyclin
D1, in turn, was expressed in <25% of the cells in most cases (91.4%
– n=53). In only one case was cyclin D1 expressed in 51–75% of the
cells, and no cases showed it in >75% of the cells (p<0.05) (Fig. 1).
In the melanoma cases, ROC1 expression was observed in >50%
of the cells in 45.2% of cases (n=28) and in <25% of the cells in 27.4%
of cases, whereas cyclin D1 was expressed in <25% of the cells in
45.2% of cases (n=28), and in >50% of the cells in 35.5% of cases
(n=22) (p<0.05) (Fig. 2).
There was no statistical difference between ROC1 and cyclin
D1 expression in relation to melanoma histological type (p>0.05).
Similarly, no statistical difference between ROC1 and cyclin D1
expression levels was associated with Breslow thickness (p>0.05).
However, cases with <25% of the cells expressing ROC1 protein
(33.3–35.3% of cases) predominated in Groups 1, 3, and 4, while
caseswith ROC1 expression in >75% of cells predominated inGroup
2 (66.8%) (Fig. 3). On the other hand, cyclin D1 expressionwas <25%
in Groups 1, 2, and 3, but >50% in Group 4 (70.6% of the samples).
Group 2 showed no cases with >75% of the cells expressing cyclin
D1.A signiﬁcant negative correlation was observed between ROC1
andcyclinD1expression levels regardless of neoplasia type (benign
or malignant) (p=0.0008985). Comparisons between ROC1 and
cyclin D1 expression in melanomas and melanocytic nevi are
shown in Tables 1 and 2, respectively.
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Fig. 1. ROC1 and cyclin D1 expression in melanocytic nevi (n=58) (p<0.05).
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Fig. 2. ROC1 and cyclin D1 expreIn some cases of melanoma, areas with >75% of the cells
xpressing ROC1 and <25% of cells expressing cyclin D1 were
bserved adjacent to areas wherein ROC1 was positive in <25%
f the cells, and cyclin D1 was expressed in >75% of the cells.
able 1
omparison of ROC1 and cyclin D1 expression in melanomas (n=62) (p=0.008).
Cyclin D1 protein
0–25% (%)
ROC1 protein expression
0–25% 4/17 (23.5%)
26–50% 2/5 (40%)
51–75% 5/12 (41.6%)
>75% 17/28 (60.7%)
Total (%) 28/62 (45.2%)51-75% >75%
 of proteins
in melanomas (n=62) (p<0.05).This was found to be independent of increased gene expression
(Fig. 4).
The ROC1/cyclin D1 relationship did not vary with age, gender,
or lesion site in either melanomas or melanocytic nevi (p>0.05).
expression
26–50% (%) 51–75% (%) >75% (%)
2/17 (11.7%) 7/17 (58.7%) 4/17 (23.5%)
2/5 (40%) 0/5 1/5 (20%)
3/12 (25%) 3/12 (25%) 1/12 (8.4%)
5/28 (17.9%) 3/28 (10.7%) 3/28 (10.7%)
12/62 (19.3%) 13/62 (21%) 9/62 (14.5%)
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Fig. 3. ROC1 expression in melanomas, classiﬁed according to Breslow thickness (n=62) (p>0.05).
Table 2
Comparison of ROC1 and cyclin D1 expression in melanocytic nevi (n=58) (p<0.05).
Cyclin D1 protein expression
0–25% (%) 26–50% (%) 51–75% (%) >75% (%)
0–25% 1/1 (100%) 0/1 0/1 0/1
26–50% 5/6 (83.3%) 0/6 1/6 (16.7%) 0/6
.3%)
.6%)
.4%)
I
e
w
(
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(
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(
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D
T
CROC1 protein expression
51–75% 14/15 (93
>75% 33/36 (91
Total (%) 53/58 (91
ncreased ROC1 protein expression, as compared with cyclin D1
xpression, predominated in all samples (65% of cases; n=78).
In the melanocytic nevus group, the ROC1 expression increase
as remarkably predominant in relation to cyclin D1 expression
86.2% of the cases). In melanomas, this ROC1 expression predom-
nance was also observed, but in only 45.2% of the cases (p<0.001)
Table 3).
Although ROC1 and cyclin D1 expression levels were predom-
nantly proportional in melanomas with thickness >2mm, and
lthough a great number of cases with melanomas >4mm (35.3%)
howed increased cyclin D1 expression in comparison with ROC1
evels, no statistically signiﬁcant difference was seen among the
roups (p=0.166).Only in the acral lentiginous melanoma group was cyclin D1
xpression greater than that of ROC1 in a large number of cases
40%). On the other hand, this group also showed the largest num-
er of cases with increased ROC1 expression as compared to cyclin
1 expression (50%). No statistically signiﬁcant difference in the
able 3
orrelations of the ROC1/cyclin D1 expression relationship with neoplasia type (n=120)
ROC1/cyclin D1 relationship
Increased ROC1 expression in
relation to cyclin D1 (%)
P
D
Melanocytic nevus 50/58 (86.2%)
Melanoma 28/62 (45.2%)
Total (%) 78/120 (65.0%)1/15 (6.7%) 0/15 0/15
3/36 (8.4%) 0/36 0/36
4/58 (6.9%) 1/58 (1.7%) 0/58
ROC1/cyclin D1 relationship was observed in relation to melanoma
histological type (p=0.605).
Six cases (ﬁve melanomas and one melanocytic nevus) exhib-
ited CCND1 gene ampliﬁcation. In two ampliﬁed cases, one was
acral lentiginous melanoma and the other was nodular melanoma
with Breslow thickness of >4mm. Cyclin D1 was expressed in
51–75% of the acral lentiginous melanoma cells and in >75% of the
nodular melanoma cells. In both the acral lentiginous and nodular
melanomas, ROC1 expression was present in <25% of the cells. In
the other ampliﬁedmelanomas (2 SSMand1 LMM), in one case, the
Breslow’s thickness was <1mm, in another it was 1.01–2mm, and
in the other itwas 2.01–4mm.Of these three ampliﬁedmelanomas,
two showed cyclin D1 and ROC1 expression in 51–75% of the cells,
while in the other case, cyclin D1 positivity was <25%, and ROC1
was expressed in >75% of the cells.
The sixth ampliﬁed case was a genital melanocytic nevus where
51–75% cyclin D1 expression was associated with ROC1 expression
in 26–50% of the cells (Fig. 5). This melanocytic nevus was the only
(p<0.001).
roportional ROC1 and cyclin
1 expression levels (%)
Increased cyclin D1 expression
in relation to ROC1 (%)
7/58 (12.1%) 1/58 (1.7%)
20/62 (32.3%) 14/62 (22.6%)
27/120 (22.5%) 15/120 (12.5%)
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Fig. 4. Case 1.13: superﬁcial spreading melanoma. (A) Area 1, hematoxylin–eosin,
400×. (B) Area 1, ROC1 expression in >75% of the cells. Immunostaining with anti-
ROC1antibody, cloneRB-069-P, LABVISION, 400×. (C)Area1, cyclinD1expression in
<25% of the cells. Immunostainingwith anti-cyclin D1 antibody, clone RBT14, BioSB,
400×. (D) Area 2, hematoxylin–eosin, 400×. (E) Area 2, ROC1 expression in <25% of
the cells. Immunostaining with anti-ROC1 antibody, clone RB-069-P, LABVISION,
400×. (F) Area 2, cyclin D1 expression in >75% of the cells. Immunostaining with
anti-cyclin D1 antibody, clone RBT14, BioSB, 400×. (G) Normal number of copies of
the CCND1 gene, FISH, CCND1 gene labeled in red and CEP11 in green, 1000×. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of the article.)
Fig. 4. (Continued )
G. Nai, M. Marques / Pathology – Research
Fig. 5. Case 5.56: melanocytic nevus. (A) Hematoxylin–eosin, 100×. (B) ROC1
expression between 26% and 50%. Immunostaining with anti-ROC1 antibody, clone
RB-069-P, LABVISION, 100×. (C) Cyclin D1 expression between 51% and 75%.
Immunostaining with anti-cyclin D1 antibody, clone RBT14, BioSB, 100×. (D) Area
with an increase in the number of copies of the CCND1 gene (arrow), FISH, CCND1
gene labeled in red and CEP11 in green, 1000×. (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of the article.)and Practice 207 (2011) 174–181 179
one to exhibit increased cyclin D1 expression as compared to ROC1
expression.
In the majority of melanomas with ampliﬁcation, protein
expressions were proportional (40% of the cases) or cyclin D1
expression was increased when compared with ROC1 expression
(40% of the samples). Among non-ampliﬁed melanomas, 50% of
those with >50% cyclin D1 positivity exhibited ROC1 expression in
<25% of cells (Fig. 6), and 43.7% showed ROC1 expression in >50% of
cells. No correlation between the ampliﬁcation of the CCND1 gene
and the relationship between protein expression levels was found
(p=0.500).
Discussion
The ROC1 RING ﬁnger protein (RING of Cullins), also called Rbx1
and Hrt1, is a highly stable protein that belongs to the C3H2C3 (or
RING-2) subclass of RING ﬁnger proteins and acts as an essential
subunit of ubiquitin-ligase SCF protein [13,19]. It was ﬁrst isolated
in yeast [21] and was biochemically puriﬁed as a common compo-
nent of both the human and yeast SCF complexes [16,28,30], aswell
as of the von Hippel-Lindau tumor-suppressor complex (CBCVHL or
Cul2-Elongin BC-VHL) [7,15] (for review, see Nai and Marques –
[20]).
ROC1 protein is encoded by the human gene Rbx1, which con-
tains ﬁve exons and is located on chromosome 22q13 [22]. Point
mutations in a single amino acid in the ROC1 protein domain can
completely disrupt ubiquitin-ligase activity [13,19,21,26]. It medi-
ates the degradation of substrate proteins required for cell cycle
progression, signal transduction, and tumor-suppressing activities
[7]. It plays an important role in labeling cyclin D1 for proteosomal
degradation [19,24,32].
In this study, the expression of ROC1 correlated with neoplasia
type (benign or malignant). In the melanocytic nevus group, ROC1
was expressed in >50% of cells in most cases, and in <25% of cells
in only one case. However, in the melanoma group, low ROC1 lev-
els (<25%) were seen in a large number of cases, demonstrating a
ROC1deﬁciency in this group. Nonetheless, no correlations of ROC1
expressionwith Breslow’s thickness ormelanomahistological type
were found. Cyclin D1 expression also correlated with neopla-
sia type. Moreover, in the melanoma group, cyclin D1 expression
showed no correlation with Breslow thickness or melanoma histo-
logical type.
Although no signiﬁcant correlations of Breslow thickness with
ROC1 and cyclin D1 expressions were detected, increased ROC1
positivity predominated in melanomas of 1.01–2mm thickness
while higher cyclin D1 levels were seen in melanomas thicker than
4mm. In melanomas with a Breslow thickness between 1.01 and
2mm, it is possible to observe the beginning of a neoplasia verti-
cal growth phase. The increased ROC1 expression found in tumors
of this thickness may reﬂect an attempt of the host to restrain the
progression of the lesion. Similarly, the higher expression of cyclin
D1 in melanomas over 4mm in thickness may be interpreted as
indicative of uncontrolled proliferation in thicker tumors at the full
tumorigenic phase.
A signiﬁcant negative correlation was observed between ROC1
and cyclin D1 expression in the study cases. When ROC1 expres-
sion increased, cyclin D1 expression decreased, and vice-versa.
Melanomas containing areas of high ROC1 protein expression and
low cyclin D1 positivity were observed alongside areas of high
cyclin D1 expression and low ROC1 expression, making evident the
presence of different cell clones in these lesions, as visualized by
light microscopy.
The ampliﬁcation of the CCND1 gene inmelanocytic nevi is rare,
and so is cyclin D1 expression increase [5,29]. Strikingly, one of
the melanocytic nevus cases included in this study showed CCND1
180 G. Nai, M. Marques / Pathology – Research
Fig. 6. Case 4.15: acral lentiginous melanoma. (A) Hematoxylin–eosin, 400×. (B)
ROC1 expression in <25% of the cells. Immunostaining with anti-ROC1 antibody,
clone RB-069-P, LABVISION, 400×. (C) Cyclin D1 expression in >75% of the cells,
Immunostainingwithanti-cyclinD1antibody, cloneRBT14, BioSB, 400×. (D)Normal
number of copies of the CCND1 gene, FISH, CND1 gene labeled in red and CEP11 in
green, 1000×. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of the article.)and Practice 207 (2011) 174–181
ampliﬁcation and the highest level of cyclin D1 expression of all
melanocytic cases studied (51–75%), associated with a decreased
ROC1 expression (26–50%). This case of melanocytic nevus was
observed in the genital region of a 20-year-old female. It was char-
acterized by intense junctional activity and cellularity and by areas
with morphologically distinct cells contiguous with each other in
the likeness of clones. Interpreting an isolated case is difﬁcult, but
one explanation for the partial reduction in ROC1 may be the con-
sumption of this protein for the degradation of the increased cyclin
D1 that is found in a lesion in the proliferative stage.
In this study, both melanomas with all cells ampliﬁed showed
cyclin D1 expression in >50% of cells and ROC1 expression in
<25% of cells. The lower ROC1 expression observed in the ampli-
ﬁed melanomas as compared to the ampliﬁed nevus suggests a
ROC1 deﬁciency and not just its consumption for the labeling of
the increased cyclin. This assumption is corroborated by the fact
that in focally ampliﬁed melanomas, no signiﬁcant ROC1 decrease
occurred even when cyclin D1 was increased. It is also conﬁrmed
bynon-ampliﬁed cases that showed increased cyclinD1 expression
and a signiﬁcant ROC1 decrease.
The ROC1/cyclin D1 relationship correlatedwith neoplasia type.
In melanocytic nevi, there was a predominance of increased ROC1
expression in relation to cyclin D1 (86.2% of the cases), whereas in
melanomas, ROC1 expression was higher than cyclin D1 expres-
sion in 45.2% of the cases. The only case of a melanocytic nevus in
which cyclin D1 was higher than ROC1 expression showed CCND1
ampliﬁcation, which is in contrast with the melanomas where the
majority of cases showed increased cyclin D1 as compared to ROC1
expression and no gene ampliﬁcation (85.7%). This fact, and the
absence of correlations between ROC1/cyclin D1 and gene ampli-
ﬁcation observed here, supports the idea of ROC1 deﬁciency in
melanomas as part of the phenomenon responsible for the increase
in cyclin D1.
The ampliﬁcation of the CCND1 gene is more common in acral
lentiginous melanomas, followed by SSM. In the former, ampliﬁ-
cation may occur early, even before the neoplasia in situ stage,
different fromothermelanoma types that showampliﬁcation later,
during progression [4,31]. In this study, however, even in the acral
lentiginous melanomas showing the highest proportional number
of cases of cyclin D1 increase in relation to ROC1 (40%), ROC1/cyclin
D1 was not associated with melanoma histological type or Breslow
thickness. This shows that ROC1 expression alteration may be an
event of melanoma oncogenesis not related to histological type.
Even if a correlation of ROC1/cyclin D1 relationship with Breslow
thickness does not occur, the large number of cases with ROC1
expression higher than that of cyclin D1 among melanomas <2mm
in thickness may show a stage during which the host response is
still effective in restraining tumor progression.
Of the 20 melanoma cases with proportional ROC1 and cyclin
D1 expressions (32.3%), ampliﬁcation of the CCND1 gene was
seen in only two. In the melanocytic nevus group, both proteins
were proportionally expressed in six cases (10.3%), and none of
themshowedgene ampliﬁcation. In thenon-ampliﬁedmelanocytic
nevi with proportional ROC1/cyclin D1, cyclin D1 was expressed
in <25% of cells and in most cases. On the other hand, in the
melanoma group, only ﬁve cases showed cyclin D1 in <25% of cells,
while six cases exhibited cyclin D1 expression in >50% of cells
associated with ROC1 expression also in >50% of the cells. This
ﬁnding suggests that, despite a ROC1 expression decrease in some
cases, cyclin D1 levels in melanocytic nevi remained unchanged
possibly due to a predominating cyclin D1 gene expression con-
trol mechanism. In melanomas, the mechanism regulating cyclin
D1 expression may be something other than gene expression
increase and ubiquitination failure. It might include the deﬁciency
of other proteins involved in cyclin ubiquitination, such as cullins
proteins.
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ampliﬁcations of the cyclin D1 gene to deﬁne histopathologically unrecog-G. Nai, M. Marques / Pathology – Re
In most melanocytic nevi, ROC1 protein was expressed by
75% of cells. Deﬁcient ROC1 expression was associated with skin
elanomas, where ROC1 expression negatively correlated with
yclin D1 expression, demonstrating the leading role of ROC1 in
yclin D1 degradation within these tumors.
The ROC1/cyclin D1 expression relationship correlated with
eoplasia type. In melanocytic nevi, there was a predominance of
ncreased ROC1 in relation to cyclin D1 expression, whereas in the
elanoma group, about one fourth of the cases showed increased
yclin D1 as compared to ROC1 expression.
Neither ROC1 levels nor theROC1/cyclinD1expression relation-
hip correlated with Breslow thickness or melanoma histological
ype. However, studies including a larger number of cases with
.01–2-mm-thickmelanomas and acral lentiginousmelanomas are
ecessary to determine whether these parameters actually corre-
ate.
Although this study has few cases with CCND1 gene ampli-
cation, the lower ROC1 expression observed in the ampliﬁed
elanomas compared to ampliﬁed nevi, and the great number
f non-ampliﬁed melanomas that had an increase in cyclin D1
xpression and a signiﬁcant ROC1 decrease, both suggest a ROC1
eﬁciency in melanomas.
Studies aiming at better understanding the causes of low ROC1
xpression which might increase cyclin D1 expression in skin
elanomas could highly contribute to the investigation of novel
reatments for these tumors.
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